Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088617 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KMT2AABCB1BCHEL3MBTL1 | |
| SCHEMBL24088615 | 0.86 | ALDH1A1 (0.48) | ALDH1A1KMT2AABCB1BCHEL3MBTL1 | |
| SCHEMBL26325839 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KMT2ABCHENLRP3MAPT | |
| SCHEMBL24088616 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KMT2AABCB1BCHEL3MBTL1 | |
| SCHEMBL26325841 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KMT2AABCB1BCHEL3MBTL1 | |
| SCHEMBL28914273 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KMT2AABCB1BCHENLRP3 | |
| SCHEMBL26325837 | 0.80 | BCHE (0.41) | ALDH1A1KMT2AABCB1BCHEL3MBTL1 | |
| SCHEMBL25622071 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KMT2ABCHEL3MBTL1MAPT | |
| SCHEMBL21243069 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KMT2AL3MBTL1MAPTLMNA | |
| SCHEMBL30261641 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KMT2AL3MBTL1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767314-B2 | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same | CONOPCO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767314-B2 | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same | CONOPCO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210380564-A1 | BIOENERGETIC NICOTINIC ACID GLYCEROL ESTERS, COMPOSITIONS AND METHODS OF USING SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767314-B2 | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same | PRKAG1, PRKAB1, PRKAG2 | ALDH1A1 1255/4885KMT2A 3175/4885ABCB1 4204/4885 |
| US-20210380564-A1 | BIOENERGETIC NICOTINIC ACID GLYCEROL ESTERS, COMPOSITIONS AND METHODS OF USING SAME | PRKAG1, PRKAB1, PRKAG2 | ALDH1A1 1255/4885KMT2A 3175/4885ABCB1 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.